L S Wilson

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Pancreatic cancer: total costs and utilization of health services
    L S Wilson
    University of California, San Francisco, San Francisco, California 94143, USA
    J Surg Oncol 71:171-81. 1999
  2. ncbi The economic burden of home care for children with HIV and other chronic illnesses
    Leslie S Wilson
    University of California, San Francisco, 3333 California, Box 0613, Suite 420M, San Francisco, CA 94143, USA
    Am J Public Health 95:1445-52. 2005
  3. ncbi Cost-effectiveness of intraoperative facial nerve monitoring in middle ear or mastoid surgery
    Leslie Wilson
    Health Policy and Economics, University of California San Francisco, 3333 California, Suite 420M, Box 0613, San Francisco, CA 94143, USA
    Laryngoscope 113:1736-45. 2003
  4. ncbi Modelling the cost-effectiveness of sentinel lymph node mapping and adjuvant interferon treatment for stage II melanoma
    L S Wilson
    Department of Clinical Pharmacology, University of California San Francisco, 94143 0613, USA
    Melanoma Res 12:607-17. 2002
  5. ncbi The direct cost and incidence of systemic fungal infections
    Leslie S Wilson
    Department of Clinical Pharmacy, University of California San Francisco, 3333 California Street, Suite 420M, San Francisco, CA 94118, USA
    Value Health 5:26-34. 2002
  6. ncbi Model of estimated rates of colorectal cancer from polyp growth by year of surveillance
    L S Wilson
    Department of Pharmacy, University of California, San Francisco, CA 94143, USA
    J Med Screen 8:187-96. 2001
  7. ncbi Annual direct cost of urinary incontinence
    L Wilson
    Department of Clinical Pharmacy, University of California, San Francisco, 94143 0613, USA
    Obstet Gynecol 98:398-406. 2001
  8. ncbi Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema
    L Wilson
    Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco 94143 0622, USA
    Respir Med 94:204-13. 2000
  9. ncbi Cost-effectiveness of Chagas disease interventions in latin america and the Caribbean: Markov models
    Leslie S Wilson
    Departments of Medicine and Pharmacy, University of California, San Francisco, California 94143, USA
    Am J Trop Med Hyg 73:901-10. 2005
  10. ncbi Longitudinal assessment of economic burden and clinical outcomes in acromegaly
    L S Wilson
    Department of Pharmacy, University of California, San Francisco, California 94143, USA
    Endocr Pract 7:170-80. 2001

Detail Information

Publications13

  1. ncbi Pancreatic cancer: total costs and utilization of health services
    L S Wilson
    University of California, San Francisco, San Francisco, California 94143, USA
    J Surg Oncol 71:171-81. 1999
    ..Accurate estimates of the cost of pancreatic cancer are unavailable; existing estimates are variable or not generalizable. This paper presents detailed cost estimates for pancreatic cancer by service, age, and gender...
  2. ncbi The economic burden of home care for children with HIV and other chronic illnesses
    Leslie S Wilson
    University of California, San Francisco, 3333 California, Box 0613, Suite 420M, San Francisco, CA 94143, USA
    Am J Public Health 95:1445-52. 2005
    ....
  3. ncbi Cost-effectiveness of intraoperative facial nerve monitoring in middle ear or mastoid surgery
    Leslie Wilson
    Health Policy and Economics, University of California San Francisco, 3333 California, Suite 420M, Box 0613, San Francisco, CA 94143, USA
    Laryngoscope 113:1736-45. 2003
    ..One of the major barriers to its acceptance is cost. This study evaluates the cost-effectiveness of intraoperative facial nerve monitoring during middle ear or mastoid surgery...
  4. ncbi Modelling the cost-effectiveness of sentinel lymph node mapping and adjuvant interferon treatment for stage II melanoma
    L S Wilson
    Department of Clinical Pharmacology, University of California San Francisco, 94143 0613, USA
    Melanoma Res 12:607-17. 2002
    ..In conclusion appropriate dosing of IFN therapy based on the results of SLM is a cost-effective strategy for stage II melanoma patients...
  5. ncbi The direct cost and incidence of systemic fungal infections
    Leslie S Wilson
    Department of Clinical Pharmacy, University of California San Francisco, 3333 California Street, Suite 420M, San Francisco, CA 94118, USA
    Value Health 5:26-34. 2002
    ..In this study we determined the incidence and direct inpatient and outpatient costs of systemic fungal infections (candidiasis, aspergillosis, cryptococcosis, histoplasmosis) in 1998...
  6. ncbi Model of estimated rates of colorectal cancer from polyp growth by year of surveillance
    L S Wilson
    Department of Pharmacy, University of California, San Francisco, CA 94143, USA
    J Med Screen 8:187-96. 2001
    ..Current models are unable to directly estimate changes in effects of chemoprevention on CRCs. The purpose is to develop a model to examine effects of changes in growth rates of polyps on surveillance intervals and risk of CRC...
  7. ncbi Annual direct cost of urinary incontinence
    L Wilson
    Department of Clinical Pharmacy, University of California, San Francisco, 94143 0613, USA
    Obstet Gynecol 98:398-406. 2001
    ..To estimate the annual direct cost of urinary incontinence in 1995 US dollars...
  8. ncbi Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema
    L Wilson
    Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco 94143 0622, USA
    Respir Med 94:204-13. 2000
    ..More attention to healthcare management of chronic bronchitis and emphysema is suggested, and improving inhaler and anti-smoking compliance might be important targets...
  9. ncbi Cost-effectiveness of Chagas disease interventions in latin america and the Caribbean: Markov models
    Leslie S Wilson
    Departments of Medicine and Pharmacy, University of California, San Francisco, California 94143, USA
    Am J Trop Med Hyg 73:901-10. 2005
    ..The best strategy to combat Chagas disease is combinations of vector control and a potential new drug...
  10. ncbi Longitudinal assessment of economic burden and clinical outcomes in acromegaly
    L S Wilson
    Department of Pharmacy, University of California, San Francisco, California 94143, USA
    Endocr Pract 7:170-80. 2001
    ..Thus, from the standpoint of economics and well-being, a continued aggressive attitude toward screening programs and treatment of persistently active acromegaly seems warranted...
  11. ncbi Cumulative cost pattern comparison of prostate cancer treatments
    Leslie S Wilson
    Department of Medicine, University of California, San Francisco, California 94143, USA
    Cancer 109:518-27. 2007
    ..The authors compared healthcare utilization and cost patterns of prostate cancer treatments over a span of 5.5 years in 4553 newly diagnosed patients stratified by age and risk group...
  12. ncbi Comparison of selection strategies for genetic testing of patients with hereditary nonpolyposis colorectal carcinoma: effectiveness and cost-effectiveness
    Carolina M Reyes
    Department of Clinical Pharmacy, University of California, San Francisco 94143, USA
    Cancer 95:1848-56. 2002
    ..However, testing all CRC patients for tumor MSI-H, although effective, may be prohibitively expensive. A mixed strategy is the more cost-effective approach...
  13. ncbi Cost-effectiveness of implementation methods for ELISA serology testing of Trypanosoma cruzi in California blood banks
    Leslie S Wilson
    University of California, San Francisco, California 94010 0613, USA
    Am J Trop Med Hyg 79:53-68. 2008
    ..The best strategy depends on site-specific risk. Census estimates of Hispanics do not predict donor risk well. We suggest using our screening questions to determine risk level and most cost-effective testing strategy...